Another Day, Another Opioid Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
As opioid plan shifts into high gear, FDA sets June dates for proposed abuse-deterrent opioids from Teva and Pfizer that already have missed user fee goals.